Optune Lua—For unresectable, locally advanced or metastatic, MALIGNANT PLEURAL MESOTHELIOMA (MPM)1


Discover the first FDA-approved
treatment for MPM in over 15 years2-4

STELLAR Clinical Results: Patients who used Optune Lua as first line in combination with pemetrexed + cisplatin or carboplatin achieved 18.2 months median OS with no added systemic AEs1,5

18.2 months - Primary endpoint - Median overall survival (OS) - (95% CI 12.1-25.8) across all patients treated with Optune Lua™ and pemetrexed + cisplatin/carboplatin

Optune Lua approval was based on the STELLAR study: a prospective, multicenter, single-arm, phase 2 study designed to study the safety and efficacy of Optune Lua and pemetrexed + cisplatin or carboplatin first line in patients with unresectable, locally advanced or metastatic, MPM.1,5

No systemic AEs were considered to be related to the use of Optune Lua

  • The only AE attributed to Optune Lua use was skin irritation (71% of patients); 66% mild-to-moderate and 5% severe. No SAEs were considered related to device use1,5
View STELLAR efficacy outcomes View STELLAR safety results
Discover Optune Lua
Helpful resources for you and your patients

AEs, adverse events; SAEs, serious adverse events.

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. FDA Approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. 5. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702-1709. 6. Optune Lua. Patient Information and Operation Manual for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019.

Next: FDA approval for unresectable MPM
Indications For Use
jump to isi

The Optune Lua System is indicated for the treatment of adult patients with unresect…

Leaving OptuneLua.com

Novocure® does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.